1
|
Gou ZP, Zhao YL, Zou LL, Wang Y, Shu SQ, Zhu XH, Zheng L, Shen Q, Luo Z, Miao J, Wang YS, Luo XD, Feng P. The safety and tolerability of alkaloids from Alstonia scholaris leaves in healthy Chinese volunteers: a single-centre, randomized, double-blind, placebo-controlled phase I clinical trial. PHARMACEUTICAL BIOLOGY 2021; 59:484-493. [PMID: 33899689 PMCID: PMC8086589 DOI: 10.1080/13880209.2021.1893349] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 01/12/2021] [Accepted: 02/16/2021] [Indexed: 02/06/2023]
Abstract
CONTEXT Capsule of alkaloids from the leaf of Alstonia scholaris (L.) R.Br. (Apocynaceae) (CALAS) is a new investigational botanical drug (No. 2011L01436) for bronchitis, post-infectious cough and asthma. OBJECTIVE To observe the clinical safety and tolerability of CALAS. MATERIALS AND METHODS Subjects were assigned to eight cohorts, and each received randomly CALAS or placebo in one of single ascending dose (SAD) of 8, 40, 120, 240, 360, 480, or in one of multiple ascending dose (MAD) of 40 or 120 mg, three times daily for 7 days. Each cohort contained two placebo subjects. RESULTS Sixty-two enrolled volunteers completed the study and no serious adverse events and clinically significant changes in vital signs, electrocardiography, and upper abdominal Doppler ultrasonography were observed. The ratios of treatment-emergent adverse events (TEAEs) were reported in 11/46 (23.91%) of CALAS groups and 3/16 (18.75%) of the placebo group (p > 0.05), respectively, based on the results of SAD and MAD. All TEAEs were mild, transient, and disappeared without any intervention. The TEAEs possibly related to CALAS treatment were as followings: hiccups (4/46: 8%), dry mouth and nausea (3/46: 6%), increased sleep (2/46: 4%), abdominal distension (1/46: 2%), bilirubin elevated (1/46: 2%). DISCUSSION AND CONCLUSIONS CALAS is safe and well-tolerated with no unexpected or clinically relevant safety concerns up to a single dose of 360 mg and three times daily for 7 days up to 120 mg in healthy Chinese volunteers, supporting further Phase II studies.
Collapse
Affiliation(s)
- Zhong-Ping Gou
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Yun-Li Zhao
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, People’s Republic of China
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Provincial Center for Research & Development of Natural Products; School of Chemical Science and Technology, Yunnan University, Kunming, People's Republic of China
| | - Lin-Ling Zou
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Ying Wang
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Shi-Qing Shu
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Xiao-Hong Zhu
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Li Zheng
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Qi Shen
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Zhu Luo
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Jia Miao
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Yong-Sheng Wang
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| | - Xiao-Dong Luo
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, People’s Republic of China
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Provincial Center for Research & Development of Natural Products; School of Chemical Science and Technology, Yunnan University, Kunming, People's Republic of China
| | - Ping Feng
- Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
| |
Collapse
|